Engineered liposomes to deliver nucleic acid mimics in Escherichia coli

J Control Release. 2023 Mar:355:489-500. doi: 10.1016/j.jconrel.2023.02.012. Epub 2023 Feb 14.

Abstract

Antisense oligonucleotides (ASOs) composed of nucleic acid mimics (NAMs) monomers are considered as potential novel therapeutic drugs against bacterial infections. However, bacterial envelopes are generally impermeable to naked oligonucleotides. Herein, liposomes loaded with NAMs-modified oligonucleotides (LipoNAMs) were evaluated to deliver ASOs in Escherichia coli. Specifically, we tested several surface modifications that included methoxyPEG conjugated to different lipid anchors or modification of the PEG distal ends with maleimide groups and antibodies. MethoxyPEG coated LipoNAMs showed low delivery efficiency for most bacteria, but maleimide-functionalized PEG LipoNAMs were able to deliver ASOs to nearly half of the bacterial population. Conjugation of antibodies to maleimide-functionalized PEG LipoNAMs increased 1.3-fold the delivery efficiency, enhancing the selectivity towards E. coli and biocompatibility. This work demonstrated for the first time that the coupling of antibodies to PEGylated liposomes can significantly improve the delivery of ASOs in E. coli, which might bring alternative routes for the treatment of bacterial infections in the future.

Keywords: Antisense oligonucleotides; Cationic liposomes; Immunoliposomes; Nucleic acid analogues; PEGylation; bacteria.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Escherichia coli / genetics
  • Liposomes*
  • Maleimides
  • Nucleic Acids*
  • Oligonucleotides
  • Oligonucleotides, Antisense

Substances

  • Liposomes
  • Nucleic Acids
  • Oligonucleotides
  • Oligonucleotides, Antisense
  • Maleimides